Patents
Literature
24 results about "Avidity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In biochemistry, avidity refers to the accumulated strength of multiple affinities of individual non-covalent binding interactions, such as between a protein receptor and its ligand, and is commonly referred to as functional affinity. As such, avidity is distinct from affinity, which describes the strength of a single interaction. However, because individual binding events increase the likelihood of other interactions to occur (i.e. increase the local concentration of each binding partner in proximity to the binding site), avidity should not be thought of as the mere sum of its constituent affinities but as the combined effect of all affinities participating in the biomolecular interaction. A particular important aspect relates to the phenomenon of 'avidity entropy'. Biomolecules often form heterogenous complexes or homogeneous oligomers and multimers or polymers. If clustered proteins form an organized matrix, such as the clathrin-coat, the interaction is described as a matricity.
Detection reagents, kits, and methods for simultaneously improving sensitivity and broadening detection range in competitive immunoassays.
This application relates to a detection reagent, kit, and method that simultaneously improves sensitivity and broadens the detection range in competitive immunoassay. The reagent includes a detection antibody bound to luminescent microspheres that specifically binds to analyte molecules in the sample, and two sets of labeled antigens containing the same competing antigen and labeled molecules of different molecular weights bound to it. The competing antigen competes with the analyte molecule for binding to the detection antibody, and the affinity of the competing antigen for binding to the detection antibody is higher than that of the analyte molecule for binding to the detection antibody. The technical solution of this application, by using two sets of labeled antigens with different affinities, ensures that the labeled antigens that play a dominant role in samples with varying concentrations of analyte molecules differ. This is suitable for competitive immunoassay of small molecule antigens or haptens in both low-concentration and high-concentration samples, and can broaden the detection range while ensuring high functional sensitivity.
Owner:CHEMCLIN DIAGNOSTICS CO LTD
BCMA binding protein, bispecific antibody, preparation method, and use
PCT designated stageWO2026021533A1Hybrid immunoglobulinsAntibody ingredientsAntiendomysial antibodiesHeavy chain
Provided are a BCMA binding protein, a bispecific antibody, a preparation method, and a use. The BCMA binding protein comprises a heavy chain variable region and a light chain variable region. The light chain variable region comprises LCDR1, LCDR2, and LCDR3; and the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3. The BCMA binding protein of the present invention has good specific affinity, binds better to a tumor cell line than a control antibody, and has an internalization effect better than that of the control. The bispecific antibody effectively targets both human BCMA and human CD3.
Owner:HARBOUR BIOMED (SHANGHAI) CO LTD
Anti-Claudin18.2 antibodies and methods of making and using same
PendingCN121464158AAntibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAntigen Binding Fragment
An isolated monoclonal antibody (mAb) or antigen binding fragment thereof having binding specificity for CLDN18 wherein the isolated mAb or antigen binding fragment thereof selectively binds to CLDN18.2 with a measurable affinity and affinity, but not to CLDN18.1.
Owner:SYSTIMMUNE INC
Means and methods for determining cellular avidity
The dynamics of cell-cell interaction and the formation of a cell bonds involves many interaction partners, a multitude of ligands and receptors including e.g. a specific interaction between e.g. a CAR and a target antigen. This interaction is believed to be highly complex and dependent on many factors such as receptor and antigen density, steric interactions, membrane and receptor mobility, etc. The present inventors delineated from a mathmetical model which best describes the cell-cell interaction and formation of cell-cell bonds. This model most accurately describes the relation between cell fraction bounds and incubation time and allows for highly improving cellular avidity measurements, in particular when performing high throughput measurements, and, provides for a highly useful cellular avidity metric.
Owner:LUMICKS CA HLDG BV
Radiopharmaceutical composition targeting glypican 3 and its use
Radiopharmaceuticals and conjugates targeting GPC3, as well as their compositions and uses, are provided herein. In one embodiment, a conjugate comprising a peptide having avidity to GPC3 and a metal chelating agent configured to bind to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. The conjugate described herein may further comprise a radionuclide. In one embodiment, a radiopharmaceutical comprising a peptide and a metal chelating agent binding to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. Methods for treating cancer by administering the radiopharmaceuticals, conjugates, and compositions thereof are further provided herein.
Owner:RAYZEBIO INC
Biparatopic Anti-CD38 antibodies and antibody drug conjugates
PCT designated stageWO2026080859A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAntibody fragments
Provided herein are, inter alia, antibodies (e.g., humanized antibodies, chimeric antibodies, monoclonal antibodies, biparatopic antibodies, antibody fragments (e.g., Fab')), which bind CD38 with high efficiency and specificity. Inter alia, are provided biparatopic antibodies that bind CD38 specifically and effectively. The biparatopic antibodies provided herein may have an increased binding avidity relative to the monoclonal antibodies they are derived from and are specifically useful for therapeutic and diagnostic purposes.
Owner:CITY OF HOPE
Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
PendingEP4466020A4Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsAntiendomysial antibodiesReceptor
Owner:LYVGEN BIOPHARMA HOLDINGS LIMITED
Radiopharmaceuticals targeting the somatostatin receptor 2 and their uses
This document provides peptides and conjugates (e.g., radiopharmaceutical conjugates) that have avidity for a somatostatin receptor and their uses. The conjugate may comprise a 6-residue peptide, such as a 6-residue monocyclic peptide, a metal chelating agent, and optionally, a linker connecting the peptide to the chelating agent. The radiopharmaceutical conjugate may further comprise a radionuclide attached to the metal chelating agent.This document also provides methods for preparing the conjugates and methods for treating cancer by administering the described conjugates to a subject in need. The radiopharmaceutical conjugate may further comprise a radionuclide bound to the metal chelating agent. This document also provides methods for preparing the conjugates and methods for treating cancer by administering the described conjugates to a subject in need.
Owner:RAYZEBIO INC
Multivalent trident aptamers for molecular recognition, methods of making and uses thereof
PendingUS20260098270A1Organic active ingredientsMicrobiological testing/measurementAptamerBiochemistry
Multivalent trident aptamers comprising the general formula [A-SA]2 or 3-L-[SB-B] in which a central branched linker molecule (L) possesses 2 or 3 variable arms ([A-SA]2 or 3), and a root ([SB-B]), connected by a central carbon atom, to provide enhanced affinity and / or avidity with a target are described, as well as methods of making and using the multivalent trident aptamers are provided.
Owner:MCMASTER UNIV
Anti-claudin 18.2 antibody, and its manufacturing method and use.
PendingJP2026518213AOrganic active ingredientsFungiAntiendomysial antibodiesAntigen Binding Fragment
An isolated monoclonal antibody (mAb) or antigen-binding fragment thereof having binding specificity to CLDN18, wherein the isolated mAb or antigen-binding fragment selectively binds to CLDN18.2 with measurable affinity and avidity, but does not bind to CLDN18.1.
Owner:SYSTIMMUNE INC
Unnatural base dna aptamers targeting bacillus cereus 5 / b / 6 metallo-beta-lactamase and methods of screening the same
ActiveCN121825978BMicrobiological testing/measurementBiological material analysisBase JPhosphorylation
The application discloses a non-natural base DNA aptamer targeting Bacillus cereus 5 / B / 6 metal beta-lactamase and a screening method thereof. The screening method uses dNaMTP and dTPT3TP, or dCNMOTP and dTPT3TP as non-natural base nucleoside triphosphate substrates, uses OneTaq DNA polymerase to amplify a DNA library containing non-natural bases, and uses lamda exonuclease to degrade 5' end phosphorylated DNA chains in PCR products, so as to obtain two ssDNA libraries. The non-natural base DNA aptamer targeting Bacillus cereus 5 / B / 6 metal beta-lactamase is screened based on the libraries, and three non-natural base DNA aptamers with a length of 70 nt are obtained. The results of a biological membrane layer interference analysis show that the three non-natural base DNA aptamers have good binding affinity to Bacillus cereus 5 / B / 6 metal beta-lactamase.
Owner:SOUTH CHINA UNIV OF TECH
Method for improving nucleic acid sequencing quality by eliminating nucleic acids with deaminated bases from library and method for sequencing in which complexes of primers, polymerases and labelled probes are bound to concatemers
The present disclosure provides methods for reducing sequencing errors comprising one or any combination of: (i) removing deaminated bases in any nucleic acid molecule throughout a library preparation workflow which includes immobilised splints which bind to the library, the use of a compaction oligonucleotide, optionally with an intervening sequence, formation of closed circular nucleic acids, creating gaps using glycosylase and lyase activities at positions with deaminated bases. The library may be sequenced using pairwise sequencing, e.g. with dark sequencing and / or sequencing using a multivalent labelled probe for the formation of an avidity molecule and soluble primer and polymerase. Method for sequencing concatemers in which the concatermers are contacted with polymerases, soluble primers and a multivalent labelled molecule which forms a complex with the polymerase. Detecting polymerase position and nucleobase bound to the polymerase in the complex. These methods generate higher quality base calls during downstream sequencing workflows.
Owner:ELEMENT BIOSCIENCES INC
Radiopharmaceutical compositions targeting phosphatidylinositol proteoglycan-3 and uses thereof
PendingCN121605115APeptide sourcesImmunoglobulins against cell receptors/antigens/surface-determinantsRadioactive drugPharmaceutical Substances
The present invention provides radiopharmaceuticals and conjugates targeting GPC3 as well as compositions and uses thereof. In one aspect, provided herein are conjugates comprising a peptide having affinity for GPC3 and a metal chelating agent configured to bind to a radionuclide. The conjugates described herein may further comprise a linker linking the chelating agent and the peptide. The conjugates described herein may further comprise radionuclides. In one aspect, provided herein is a radiopharmaceutical comprising a peptide and a metal chelating agent that binds to a radionuclide. The conjugates described herein may further comprise a linker linking the chelating agent and the peptide. Further provided herein are methods of treating cancer by administering the described radiopharmaceuticals, conjugates, compositions thereof.
Owner:LEIZEBIO CO LTD
Means and methods for antibody discovery
The current invention relates to cell-cell interaction and in particular to cellular avidity. Provided are improved means and methods to study cell-cell interaction and characterizing cellular avidity. Highly advantageously, it was shown that cellular avidity methods allowed to enrich for B cells expressing an antigen-specific antibody from B cells obtained from subjects exposed to said antigen, e.g. via infection, vaccination, or immunization. Hence, improved means and methods for use in antibody discovery and development are provided. Highly advantageously, it was also shown that cellular avidity methods allowed to determine immune responses against antigens from B cells obtained from subjects exposed to said antigen, e.g. via infection, vaccination, or immunization. Hence, improved means and methods for determining immune response are also provided.
Owner:LUMICKS CA HLDG BV
Monoclonal antibody aiming at new bunyavirus NP protein and application thereof
The invention discloses a monoclonal antibody aiming at a new bunyavirus NP protein and application of the monoclonal antibody. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. One aspect of the invention provides a pair of paired monoclonal antibodies for detecting the NP protein of the new bunyavirus, one of the paired antibodies is subjected to humanized IgM modification, and the modification can improve the affinity and weaken the HAMA effect. The paired antibody is applied to development of an in-vitro diagnostic kit, and is applied to qualitative detection of the NP protein of the new bunyavirus in blood.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV +1
Multivalent CD301 fusion protein based on optimized peptide linker, functionalized magnetic bead and application of multivalent CD301 fusion protein and functionalized magnetic bead in CTC capture
The invention relates to the technical field of biomedical detection, and discloses a multivalent CD301 fusion protein based on an optimized peptide linker, a functionalized magnetic bead and application of the functionalized magnetic bead in CTC capture, the protein is of a single polypeptide chain structure and comprises a plurality of CD301 carbohydrate recognition domains which are connected in series through the peptide linker, and preferably, the protein is in a tetramer form. According to the invention, peptide linkers connecting each recognition domain are specially designed, including optimized flexible linkers or rigid linkers rich in O-glycosylation sites (such as hCG [beta] CTP), so as to regulate the spatial orientation of the domains. By immobilizing the directionally arranged multivalent protein on the surface of the magnetic particle, the binding affinity with a Tn antigen on the surface of a tumor cell is remarkably enhanced by utilizing a multivalent synergistic effect. The method provided by the invention can effectively capture the low EpCAM expression CTC with epithelial-mesenchymal transition (EMT), and has extremely high binding stability under the shear force of blood fluid.
Owner:CHONGQING ZHENJIAYI BIOTECHNOLOGY CO LTD
Engineered Ligand promotes TREM1-dependent anti-tumor immunity through cross-presentation
The present invention provides a recombinant multivalent TREM1 agonist, termed Tetra-CNX, designed to engage and activate TREM1 on myeloid cells. The ligand comprises multiple calnexin luminal domains assembled in a multimeric configuration, enabling high-avidity receptor binding and downstream SYK-dependent signaling. Upon activation, Tetra-CNX enhances lysosomal remodeling and promotes efficient antigen uptake, processing, and presentation via MHC class I and II pathways. This invention enables improved priming of CD4+ and CD8+ T cells and facilitates immune activation in contexts requiring enhanced antigen presentation, including but not limited to cancer, infectious diseases, and vaccine responses. Pharmaceutical compositions and methods of use are provided for modulating myeloid cell function and adaptive immunity through TREM1-targeted intervention.
Owner:NAT YANG MING CHIAO TUNG UNIV
Non-natural base DNA aptamer of targeted bacillus cereus 5 / B / 6 metal beta-lactamase and screening method of non-natural base DNA aptamer
ActiveCN121825978AMicrobiological testing/measurementBiological material analysisBase JPhosphorylation
The invention discloses a non-natural base DNA aptamer targeting bacillus cereus 5 / B / 6 metal beta-lactamase and a screening method of the non-natural base DNA aptamer. The screening method comprises the following steps: respectively taking dNaMTP and dTPT3TP, or dCNMOTP and dTPT3TP as non-natural base nucleoside triphosphate substrates, and amplifying a DNA library containing non-natural bases by utilizing OneTaq DNA polymerase; the method comprises the following steps: carrying out PCR (Polymerase Chain Reaction) reaction on bacillus cereus 5 / B / 6 metal beta-lactamase, degrading 5 '-end phosphorylated DNA chains in a PCR product by virtue of lamda exonuclease to obtain two ssDNA libraries, and screening non-natural base DNA aptamers targeting bacillus cereus 5 / B / 6 metal beta-lactamase on the basis of the libraries to obtain three 70 nt non-natural base DNA aptamers. A biological membrane layer interference analysis result shows that the three non-natural base DNA aptamers have good binding affinity to bacillus cereus 5 / B / 6 metal beta-lactamase.
Owner:SOUTH CHINA UNIV OF TECH
Immune cell engager formats and methods of use
PCT designated stageWO2026097036A2Antibody mimetics/scaffoldsImmunoglobulinsCancer cellSpecific immunity
Disclosed herein are multispecific immune cell engagers, such as multispecific T cell engagers. Multispecific immune cell engagers comprise one or more (e.g., two) target binding domains that bind to target molecules on immune effector cells, such as T cells, and one or more (e.g., two or three) binding domains that bind to target molecules on target cells, such as cancer cells or B cells. Specificity for multiple target cell targets can result in prevention of antigen escape, and other favorable properties, such as improved affinity or avidity for target cells. Certain multispecific immune receptors also induce costimulatory signaling in immune effector cells to prevent or reduce antigen-independent relapse.
Owner:ACERA THERAPEUTICS INC
Radiopharmaceuticals targeting somatostatin receptor 2 and uses thereof
Provided herein are peptides and conjugates (e.g., radiopharmaceutical conjugates) having avidity for a somatostatin receptor and uses thereof. The conjugate can comprise a 6-mer peptide, such as a monocyclic 6-mer peptide, a metal chelator, and optionally a linker connecting the peptide to the chelator. The radiopharmaceutical conjugate can further comprise a radionuclide bound to the metal chelator. Further provided herein are methods of preparing the conjugates, and methods of treating cancer by administering the described conjugates to a subject in need thereof.
Owner:RAYZEBIO INC
Multispecific immune cell engagers
PCT designated stageWO2026097024A1Hybrid immunoglobulinsAntibody mimetics/scaffoldsCancer cellMedicine
Disclosed herein are multispecific immune cell engagers, such as multispecific T cell engagers. Multispecific immune cell engagers comprise one or more (e.g., two) binding domains that bind to target molecules on immune effector cells, such as T cells, and one or more (e.g., two or three) binding domains that bind to target molecules on target cells, such as cancer cells or B cells. Specificity for multiple target cell targets can result in prevention of antigen escape, and other favorable properties, such as improved affinity or avidity for target cells. Certain multispecific immune receptors also induce costimulatory signaling in immune effector cells to prevent or reduce antigen-independent relapse
Owner:ACERA THERAPEUTICS INC
A molecular switch to tune the avidity of immune cells to their target
PendingUS20260021182A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyDiseaseNucleotide
Disclosed herein, in some aspects, are engineered avidity switch polypeptides, polynucleotides encoding the same, immune cells comprising the same, and compositions comprising the polypeptides, polynucleotides, and / or immune cells. In certain embodiments, engineered avidity switch polypeptides comprise one or more CD6 derived amino acid sequences and / or domains. In certain embodiments, engineered avidity switch polypeptides comprise engineered arrangements of extracellular domains of CD6 polypeptides. Also disclosed are methods for disease treatment, such as cancer treatment, comprising administering such immune cells and / or compositions to a subject in need thereof.
Owner:BAYLOR COLLEGE OF MEDICINE
Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
PendingUS20250388669A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseCancer cell
Immune cell receptors such as those in the tumor necrosis factor receptor (TNFR) superfamily member or CD3 play important roles in controlling immune responses against pathogens or diseased cells, including cancer cells and pathogen infected cells. Antibodies targeting such immune cell receptors have been used for modulating immune responses and disease treatment. Multi-specific, optionally multi-valent, antibodies comprising at least one antigen binding moiety in Fv format. Also provided herein are methods for making such multi-specific antibodies and uses thereof for modulating immune responses and treating diseases such as cancer.
Owner:LYVGEN BIOPHARMA HOLDINGS LIMITED
Compositions and methods for optimized igg production
PendingUS20250369983A1Viral antigen ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsImmunoglobulin heavy chainEpitope
The present disclosure provides a method of producing an antigen-binding protein (e.g., antigen-binding region, immunoglobulin, or antigen-binding fragment thereof), including cloning from a single B-cell at least one immunoglobulin heavy chain or an antigen-binding fragment thereof and at least one immunoglobulin light chain or an antigen-binding fragment thereof; producing at least one antigen-binding protein expressing host cell that expresses one or more of a single antigen-binding protein comprising one of the at least one immunoglobulin heavy chain or antigen-binding fragment thereof and one of the at least one immunoglobulin light chain or antigen-binding fragment thereof; screening / examining each of the at least one antigen-binding protein expressing host cell for the specificity, avidity, and / or affinity of the antigen-binding protein for a protein or peptide epitope of interest to find or select at least one antigen-binding protein; and expressing the at least one antigen-binding protein of interest in a eukaryotic cell.
Owner:ABBRATECH INC